DEF: Celcuity 2026 Proxy Statement Overview

Celcuity Inc. has issued its 2026 proxy statement detailing proposals for director elections, executive compensation, and new equity incentive plans.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for May 14, 2026.
• Stockholders will vote on the election of eight directors, including new nominee Charles R. Romp.
• The company seeks ratification of Boulay PLLP as the independent registered public accounting firm for 2026.
• Proposals include an advisory vote on executive compensation and the approval of the 2026 Stock Incentive Plan.
• The company is requesting approval for an Amended and Restated 2017 Employee Stock Purchase Plan (ESPP) to increase available shares by 289,199.
• As of March 17, 2026, there were 48,336,675 shares of common stock outstanding.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a standard administrative proxy filing. While the company shows significant stock price appreciation, the lack of revenue and continued reliance on equity dilution for compensation are typical risks for the sector.

Positives

• The company has maintained a majority of independent directors on its Board.
• The 2026 Stock Incentive Plan includes robust governance features, such as a prohibition on repricing options without stockholder approval.
• The company has implemented a clawback policy for incentive-based compensation.
• The 2026 Plan includes a 'no liberal share recycling' provision to protect stockholder interests.
• The company's common stock price increased by approximately 612% from December 31, 2022, to December 31, 2025.

Negatives

• The company continues to incur significant net losses as a clinical-stage biotechnology firm.
• The company has not generated any revenue from product sales to date.
• The 2026 Stock Incentive Plan and ESPP will result in further potential dilution for existing shareholders.
• The company does not currently have a lead independent director, with the CEO serving as Chairman.

Risks

• The company is a clinical-stage biotechnology firm with no product revenue, relying on continued capital access.
• The company's stock price is subject to volatility and may not reflect the achievement of internal milestones.
• The company's business strategy is long-term, and failure to achieve clinical development goals could adversely impact value.
• The company is subject to risks related to the competitive biopharmaceutical labor market, necessitating significant equity-based compensation.

Future Outlook

The company intends to continue executing its clinical development and commercialization plans, requiring competitive compensation to attract and retain talent. It anticipates the need for the 2026 Stock Incentive Plan to support future growth over the next three years.

Management Comments

• The Board believes that equity awards are critical to attract, motivate, and retain talented leaders and align their interests with stockholders.
• The Board believes the current leadership structure, with the CEO as Chairman, promotes unified direction and effective execution of strategic initiatives.

Industry Context

StockSavvy.ai notes that Celcuity's reliance on equity-based compensation is standard for clinical-stage biotech firms, which often lack cash flow and must preserve capital for R&D while incentivizing key personnel.

Comparison to Industry Standards

• The company's use of an 'evergreen' provision in its equity plans is common among emerging growth biotechnology companies.
• The 4.7% burn rate in 2025 is consistent with the high-growth, R&D-intensive nature of the biopharmaceutical sector.
• The absence of employment or change-in-control agreements for named executive officers is less common than in larger, established pharmaceutical companies.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Indemnification agreements are in place for all directors and executive officers.
• Richard Nigon, a director, holds warrants issued in connection with pre-IPO financings.

Stakeholder Impact

• Shareholders face potential dilution from the proposed 2026 Stock Incentive Plan and the amended ESPP.
• Employees benefit from the proposed expansion of the ESPP and the new stock incentive plan.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on May 14, 2026.
• Implement the 2026 Stock Incentive Plan upon stockholder approval.
• Execute the Amended and Restated 2017 Employee Stock Purchase Plan upon stockholder approval.

Key Dates

Keywords

Celcuity, Proxy Statement, Biotechnology, Oncology, Equity Incentive Plan, Corporate Governance, Clinical-stage